On its Q3 2025 earnings call, then-CEO Ashley Cordova indicated TRIDENT was examining “the benefit of starting Tumor Treating Fields concurrently with chemo radiation in newly diagnosed GBM,” as opposed to the current practice of waiting until after the “chemo radiation cycle ends.” On January 14, 2026, during Novocure’s presentation at a healthcare conference, CEO Frank Leonard indicated they expected, for the majority of patients in the study, that “we’ll produce better duration of therapy overall than in our prior study.” He further claimed, with respect to the upcoming readouts, that the company had put itself “in a place to build additional evidence over the coming years to keep this growth going.” Several months later, on June 18, 2026, shares were falling more than 18% midday after the Company disclosed that its Phase 3 TRIDENT trial missed the primary overall survival endpoint, wiping out roughly $3.30 per share in value.